Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Operating Leases (2023 - 2025)

Immunome's Operating Leases history spans 3 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 19.17% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $3.9 million, down 19.17%, while the annual FY2025 figure was $3.9 million, 19.17% down from the prior year.
  • Operating Leases reached $3.9 million in Q4 2025 per IMNM's latest filing, down from $4.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $4.8 million in Q1 2025 to a low of $1.2 million in Q1 2024.
  • Average Operating Leases over 3 years is $3.0 million, with a median of $3.2 million recorded in 2024.
  • The largest YoY upside for Operating Leases was 295.52% in 2025 against a maximum downside of 19.17% in 2025.
  • A 3-year view of Operating Leases shows it stood at $1.3 million in 2023, then soared by 255.9% to $4.8 million in 2024, then fell by 19.17% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Operating Leases are $3.9 million (Q4 2025), $4.0 million (Q3 2025), and $4.1 million (Q2 2025).